Cipla, a leading drug maker,  on August 12 announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the United States Food and Drug Administration (US FDA).

Cipla's Difluprednate Ophthalmic Emulsion 0.05% is AB-rated generic therapeutic equivalent version of Novartis Pharmaceutical Corporation’s Durezol. It is used in the treatment of inflammation and pain associated with ocular surgery and treatment of endogenous anterior uveitis.

According to IQVIA (IMS Health), Durezol had US sales of approximately USD 106 million for the 12-month period ending June 2021.

Shares of the company declined Rs 5.20, or 0.57%, to settle  at  Rs 905.05.  The total volume of shares traded  was 179, 650 at  the BSE (Thursday).